📈 Stocks & Economy🌐 Global
AbbVie in Talks to Buy Biotech for $10.9 Billion to Win New Eczema Drug
MarketWatch·Saturday, 20 June 2026
AbbVie is reportedly trying to acquire a biotech company developing an experimental atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report cited by MarketWatch. Atopic dermatitis, commonly known as eczema, affects millions of people globally. The deal would add an early-stage but promising treatment to AbbVie's portfolio.
Why It Matters
Eczema is one of the most common chronic skin conditions in the world. A major pharmaceutical acquisition of this size signals where big drugmakers see the next wave of treatments heading.
🔒 Potential Impact + source link
Subscribe to unlock the impact analysis and original source for every story.
More from Stocks & Economy
- Iran Shuts Strait of Hormuz — Oil Prices and Indian Economy Brace for Impact
- Hawkish Fed Under Warsh Signals Possible Rate Hike in 2026 — Bad News for Indian Markets
- European Stocks Surge on Middle East Peace Hopes — What It Means for Global Portfolios
- China Pushes AI Safety Agenda at G7 — Without Being in the Room